Johnson & Johnson ordered to pay $417 mn to woman in trial over talc cancer risks

Johnson & Johnson, which plans to appeal the verdict, countered that studies and federal agencies have not found that its talc products are carcinogenic

Reuters August 23, 2017 09:41:29 IST
Johnson & Johnson ordered to pay $417 mn to woman in trial over talc cancer risks

A California jury on Monday ordered Johnson & Johnson to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.

The Los Angeles Superior Court jury's verdict in favor of California resident Eva Echeverria was the largest yet in lawsuits alleging J&J failed to adequately warn consumers about the cancer risks of its talc-based products.

Johnson  Johnson ordered to pay 417 mn to woman in trial over talc cancer risks

Reuters

"We are grateful for the jury's verdict on this matter and that Eva Echeverria was able to have her day in court," Mark Robinson, her lawyer, said in a statement.

The verdict included $70 million in compensatory damages and $347 million in punitive damages. It was a major setback for J&J, which faces 4,800 similar claims nationally and has been hit with over $300 million in verdicts by juries in Missouri.

"We will appeal today's verdict because we are guided by the science, which supports the safety of Johnson's Baby Powder," J&J said.

Echeverria's lawsuit was the first out of hundreds of California talc cases to go to trial.

The 63-year-old claimed she developed terminal ovarian cancer after decades of using J&J's products. Her lawyers argued J&J encouraged women to use its products despite knowing of studies linking ovarian cancer to genital talc use.

J&J's lawyers countered that studies and federal agencies have not found that talc products are carcinogenic.

The trial follows five prior ones in Missouri state court, where many lawsuits are pending.

J&J lost four of those trials and, along with a talc supplier, has been hit with $307 million in verdicts. Before Monday, the largest verdict was for $110 million.

The Missouri cases, which have largely been brought by out-of-state plaintiffs, have faced jurisdictional questions after the U.S. Supreme Court issued a ruling in June that limited where personal injury lawsuits can be filed.

In a decision in a case involving Bristol-Myers Squibb Co, the Supreme Court said state courts cannot hear claims against companies that are not based in the state when the alleged injuries did not occur there.

The ruling prompted a St. Louis judge, at New Jersey-based J&J's urging, to declare a mistrial in the talc case already underway.

The judge has nonetheless left the door open for the plaintiffs to argue they still have jurisdiction based on a Missouri-based bottler J&J used to package its products.

The case is Echeverria et al v. Johnson & Johnson, Los Angeles Superior Court, No. BC628228.

Updated Date:

also read

Euro 2020: Kevin Pietersen slams racial abuse of Black English footballers after defeat in final
Sports

Euro 2020: Kevin Pietersen slams racial abuse of Black English footballers after defeat in final

Pietersen, a former national team captain, got caught in the chaos that broke out after England's loss to Italy in the penalty shootout of the summit showdown at Wembley.

Racist abusers to be banned from football stadiums, says British Prime Minister Boris Johnson
Sports

Racist abusers to be banned from football stadiums, says British Prime Minister Boris Johnson

The proposed change to football banning orders follows a deluge of abuse being directed at several black England players after the team's defeat in the Euro 2020 final against Italy on Sunday.

What the indemnity clause is and how its waiver will accelerate arrival of COVID-19 vaccines in India
India

What the indemnity clause is and how its waiver will accelerate arrival of COVID-19 vaccines in India

Given that Pfizer's mRNA vaccine is the only jab to have been approved for use in children aged 12 and 17, the 50 million doses the govt aiming to procure should be allow India vaccinate most of its children in that age group